Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤DUET-AD 6-month readout expected March 2027 after database lock on February 8
- ➤Annovis raised $21.0 million, expected to fund operations through DUET-AD data readout
- ➤DUET-AD fully enrolled with 862 early Alzheimer’s disease patients
- ➤Cash fell to $2.8 million from $19.5 million at December 31, 2025
- ➤Third-quarter R&D expenses rose to $15.8 million from $6.3 million year over year
Expert Statements
Maria Maccecchini, President and CEO of Annovis Bio
“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA),”
Maria Maccecchini, President and CEO of Annovis Bio
“We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027.”
Maria Maccecchini, President and CEO of Annovis Bio
“The team is working very hard to deliver clean data and an on-time readout.”
* Last patient, last visit of the 6-month treatment period in the Phase 3 DUET-AD study is scheduled for December 31, 2026, with database lock on February 8, 2027, and data readout in March 2027 * Parkinson’s disease open-label extension (OLE-PD) study has enrolled 326 patients, with enrollment scheduled to close on January 29, 2027 * Annovis raised $21.0 million in gross proceeds through an underwritten public offering, which is expected to fund operations through the 6-month data readout from DUET-AD MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.